Skip to main content

A case for studying rare disorders

Last week I blogged about some of the interesting papers I’d found on my latest troll through the medical papers (the ones I can get to anyway).

One thing I left out, mostly because it didn’t fit with the topic at hand, were the papers I found where the researchers are studying HPS, but not so much for HPS’s sake. Several of the researchers were using the protein trafficking problem of HPS as a model to study cancer cells that don’t respond to typical cancer therapies. The science, as usual, was a bit beyond my humble understanding. I suppose the researchers are trying to better understand why certain types of cancer are resistant to therapy.

There were several of these papers. In fact, last year a researcher from Germany studying cancer contacted the Network and asked if we could help him get some blood samples. After his research was looked at by some of our science folks, I volunteered some of my blood. If you could help a cancer researcher with a vile of blood, how could you refuse?

And who knows – even though they aren’t studying HPS exactly, as they work with their HPS mice etc, perhaps they’ll stumble upon another clue for the great mystery.

I bring this up for another reason too, however. There are those who don’t see the value in funding research on a rare disease like ours. They’d rather go after the big name diseases that they feel impact more people. The thing is, however, there are many times in history where studying a rare disease has yielded that magic clue to an ailment much more common. By ignoring disorders like ours, they could be overlooking that critical clue that could make all the difference.

Comments

Popular posts from this blog

Ratner's Cheesecake

Here's another recipe from Toby! Thanks Toby......and I'll get the others posted soon! Ratner's Cheesecake and plain cookies Ratner's was a Jewish dairy restaurant in the lower East Side of Manhattan. This recipe, from my disintegrating, no longer in print Ratner's cookbook, is the closest I've ever gotten to reproducing the rich, heavy cheesecake my mother made when I was a kid. It's worth the time it takes to prepare and every last calorie. Dough Can be prepared in advance. Makes enough for two cakes. Can be frozen or used to make cookies – see recipe below. 1 cup sugar 1 teaspoon vanilla extract 1 cup shortening 1 teaspoon lemon extract 1 cup butter 2 eggs 3 cups sifted cake flour ½ teaspoon salt 2 cups all purpose flour 1 teaspoon baking powder 1. In a bowl, combine all ingredients with hands. Refrigerate 3 -4 hours, or preferably overnight. Filling (for

The next generation with Hermansky-Pudlak Syndrome

I'm so behind on posting about the trip to Puerto Rico. Since the episode of Mystery Diagnosis on Hermansky-Pudlak Syndrome ran right after we got home, it's been a little busy. These, however, are my favorite pictures from Puerto Rico. I know, not pretty senery etc - but these little guys and gals inspire me. They are the next generation of folks with HPS, and if we keep up the hard work, they will live better lives because of it. They motivate me.

Some good news about Pirfenidone

Below is a press release from Intermune, the company that makes Pirfenidone. They have essentially reviewed the various clinical trials going on, and decided that Pirfenidone is safe and well tolerated. That would pretty much go along with what we've observed in the HPS community as well. We have a few folks that have been on the drug since the late 90s and continue to do well. Of course, as a journalist, I do have to say consider the source - but at the same time, as someone in a Pirfenidone trial, it's good to know. Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting - Analysis shows safety and tolerability of pirfenidone across four clinical trials - VIENNA, Sept. 14 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced that the results of a comprehensive review of safety data from four clinical studies were presented at the 2009 European Respiratory Society Annual Congress in Vienna, Austria